Brief: NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
19/10/2023 15:04
Oct 19 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH ANNOUNCES POSTER PRESENTATION AT THE 16TH
ANNUAL
CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
Source text for Eikon: ID:nGNX2JW7tG
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program